Moreover, in the CRUISE trial, which investigated the efficacy and safety of ranibizumab injections in patients with macular edema secondary to CRVO, the visual prognosis was poor when anti-VEGF therapy was delayed [121]. This evidence concerns the gene VEGFA and macular retinal edema.